Branched Chain Amino Acids (Isoleucine, Leucine, Valine) are the three branched chain amino acids (BCAAs). Branched chain amino acids (BCAA) are essential amino acids and must be obtained from the diet (mainly meat, grains, and dairy).

Branched-Chain Amino Acids (BCAAs) are required for protein synthesis and are metabolized outside hepatic tissues, unlike most other essential amino acids. They are converted to branched-chain keto acids which require B-complex vitamins. BCAAs have been associated with obesity, weight loss, insulin resistance, and nonalcoholic fatty liver disease (NAFLD). 

BCAA’s are nitrogen donors, facilitate glucose uptake by liver and skeletal muscle, and enhance glycogen synthesis.

- BMI was positively associated with urine 2-hydroxyisobutyrate, isoleucine, valine, tryptophan, and tyrosine.

- Elevated urine levels were associated with higher colorectal cancer.

Volatile substances in the blood include ethanol, methanol, isopropanol, and acetone. Acetone is generally elevated in metabolic conditions such as diabetic ketoacidosis. Methanol and isopropanol are highly toxic and result from exogenous ingestion.

The presence of isopropanol indicates exposure which may result in intoxication and CNS depression. Ingestion of isopropanol can be fatal if patients do not receive immediate medical treatment.

Isosatratoxin F is another trichothecene produced by Stachybotrys chartarum. Several animal studies have shown that isosatratoxin F can cause nasal and pulmonary toxicity when administered intranasally or intratracheally. They showed that pulmonary alveolus cells were injured following intratracheal instillation of isosatratoxin F with marked changes in surfactant synthesis and secretion.

Isovalerylglycine is produced from leucine catabolism. It is further metabolized via isovaleryl-CoA dehydrogenase. This enzyme requires vitamin B2 as a cofactor.

Isovalerylglycine is produced from leucine catabolism. It is further metabolized via isovaleryl-CoA dehydrogenase. This enzyme requires vitamin B2 as a cofactor.

Isovalerylglycine is a breakdown product of leucine. 

The JAK2 Exon 12 mutation is a genetic test used to help diagnose certain myeloproliferative neoplasms (MPNs)—a group of blood disorders where the bone marrow produces too many blood cells. This mutation is most commonly associated with Polycythemia Vera, especially in individuals who do not carry the more common JAK2 V617F mutation. Testing is typically recommended when blood work shows elevated red blood cell levels or unexplained increases in hemoglobin or hematocrit.

Japanese encephalitis virus (JEV) is a flavivirus related to dengue, yellow fever and West Nile viruses, and is spread by mosquitoes (especially Culex tritaeniorhynchus).

JEV is the main cause of viral encephalitis in many countries of Asia with an estimated 100 000 clinical cases every year.

Although symptomatic Japanese encephalitis (JE) is rare, the case-fatality rate among those with encephalitis can be as high as 30%. Permanent neurologic, cognitive and behavioural sequelae occur in 30–50% of those with encephalitis.

This test measures the amount of antibodies to anti-Jo-1 in blood. It is used to help diagnose and manage muscle diseases that affects the immune system such as polymyositis (a type of chronic inflammation of the muscles) associated with autoimmune disease.

Presence of Jo-1 (antihistidyl transfer RNA [t-RNA] synthetase) antibody is associated with polymyositis and may also be seen in patients with dermatomyositis.

Polymyositis is one of a group of rare diseases called the inflammatory myopathies that involve chronic (long-standing) muscle inflammation and weakness, and in some cases, pain. Myopathy is a general term used to describe a number of conditions affecting the muscles. All myopathies can cause muscle weakness.

Jo-1 antibody is also associated with pulmonary involvement (interstitial lung disease), Raynaud phenomenon, arthritis, and mechanic's hands (implicated in antisynthetase syndrome).

Detect possible allergic responses to various substances in the environment such as animals, antibiotics, foods, grasses, house dust, mites, insects, insulin, molds, smuts, trees, and weeds; evaluate hay fever, asthma, atopic eczema, and respiratory allergy.

Kappa is a type of immunoglobulin light chain measured on the Immunofixation, Serum (NMH/LFH) panel to help identify abnormal monoclonal protein production, often associated with plasma cell or B-cell disorders. In healthy individuals, kappa and lambda light chains are produced in a balanced ratio, but an excess of kappa may indicate a monoclonal gammopathy such as multiple myeloma, MGUS (monoclonal gammopathy of undetermined significance), or related conditions. Immunofixation helps pinpoint the presence and type of monoclonal antibody by detecting kappa or lambda light chains linked to specific heavy chains like IgG, IgA, or IgM. An abnormal kappa result—especially if it appears as a monoclonal band or significantly alters the kappa/lambda ratio—can suggest a clonal proliferation of plasma cells. This marker is commonly used alongside other tests like serum free light chain assays, protein electrophoresis, and bone marrow evaluation to confirm diagnosis and guide management of monoclonal plasma cell disorders.

The Kappa Light Chain, Free, Urine test is a highly specialized diagnostic tool used extensively in the field of medical diagnostics to detect and monitor a range of hematological disorders, particularly multiple myeloma and other plasma cell dyscrasias. This test specifically measures the level of free kappa light chains present in the urine, which are small protein fragments produced by plasma cells, a type of white blood cell. Elevated levels of kappa light chains in urine can be an indicator of multiple myeloma, a cancer of plasma cells, or other related disorders. The test is crucial in both the initial diagnostic process and the ongoing monitoring of these conditions, playing a vital role in the early detection and effective management of diseases characterized by abnormal plasma cell growth.

The Kappa/Lambda ratio measures the balance between free kappa and lambda light chains in the blood and helps detect abnormal plasma cell activity. A high ratio suggests excess kappa light chain production, while a low ratio indicates excess lambda—both can signal monoclonal gammopathies like multiple myeloma or MGUS. This ratio is a key marker used alongside other tests to diagnose and monitor plasma cell disorders.

Free light chains will normally be present in the blood at low levels, with a kappa/lambda ratio of approximately 0.26 to 1.65 for individuals with normal kidney function.

Excess production of free kappa or lambda chains can alter this ratio. Monoclonal free light chains are found in serum of patients with multiple myeloma, Waldenstrom's macroglobulinemia, mu-heavy chain disease, primary amyloidosis, light chain deposition disease, monoclonal gammopathy of undetermined significance, and lymphoproliferative disorders.

When the test is used to monitor a known plasma cell disorder, a decrease in the quantity of excess light chain and a more normal kappa/lambda ratio may indicate a response to treatment.

Decreased free light chains with a normal kappa/lambda ratio may be seen with a disorder that suppresses bone marrow cell production.